January 6, 2020 / 10:41 PM / 13 days ago

CORRECTED-BRIEF-Merck's Keytruda Shows Mixed Results In Phase 3 Trial For Small Cell Lung Cancer

(Corrects headline to say Keytruda shows mixed results instead of significantly improving survival)

Jan 6 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL COMPARED TO CHEMOTHERAPY ALONE AS FIRST-LINE TREATMENT FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER

* MERCK & CO INC - PHASE 3 KEYNOTE-604 STUDY DID NOT MEET OTHER DUAL PRIMARY ENDPOINT OF OVERALL SURVIVAL

* MERCK - PHASE 3 KEYNOTE-604 TRIAL INVESTIGATING KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY MET ONE OF DUAL PRIMARY ENDPOINTS OF PROGRESSION-FREE SURVIVAL

* MERCK - TREATMENT WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY RESULTED IN STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS VERSUS CHEMOTHERAPY ALONE

* MERCK & CO INC - THERE WAS IMPROVEMENT IN OS FOR PATIENTS TREATED WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY COMPARED TO CHEMOTHERAPY ALONE

* MERCK & CO INC - OS RESULTS DID NOT MEET STATISTICAL SIGNIFICANCE PER PRE-SPECIFIED STATISTICAL PLAN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below